Source comparison
Sermorelin GHRP-2 Acetate Protocol Research: Comparison
Primary Mechanism GHRH receptor agonism → direct somatotroph stimulation Ghrelin receptor agonism + somatostatin suppression Dual-pathway: GHRH stimulation during somatostatin suppression window Synergy requires both. Neither monotherapy achieves the same IGF-
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GHRH receptor agonism → direct somatotroph stimulation
- Ghrelin receptor agonism + somatostatin suppression
- Dual-pathway: GHRH stimulation during somatostatin suppression window
- Synergy requires both. Neither monotherapy achieves the same IGF-1 elevation at equivalent doses
- Typical Dose Range (per injection)
- 200–500mcg subcutaneous
- 100–300mcg subcutaneous
- 200–300mcg sermorelin + 100–200mcg GHRP-2
- Dual protocols use lower per-peptide doses than monotherapy because synergy compensates
- Peak GH Pulse Timing
- 20–40 minutes post-injection
- 30–60 minutes post-injection
- 25–45 minutes post-injection (co-administration)
- Co-administration synchronises peaks. Sequential dosing misses the window
- IGF-1 Increase (Mean, 8 Weeks)
- 18–25% above baseline
- 12–20% above baseline
- 35–50% above baseline
- Dual protocols produce 1.5–2× the IGF-1 response of either peptide alone
- Fasting Requirement
- Minimum 3 hours pre-injection
- Minimum 3 hours pre-injection, continue 60 min post
- Insulin blunts GH release. Fasting is non-negotiable across all protocols
- Storage Stability (Reconstituted)
- 28 days at 2–8°C
- 28 days at 2–8°C (both vials)
- Temperature excursions above 8°C denature peptides invisibly. Potency loss without visual indicators